Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + hydroxychloroquine
- Development stage
- Unknown
- Lead developer
- Chung-Ang University Gwangmyeong Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspirin + hydroxychloroquine is a combination of two small molecule drugs, each with distinct mechanisms of action. Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased synthesis of prostaglandins and thromboxanes, which results in anti-inflammatory, analgesic, antipyretic, and antiplatelet effects. Hydroxychloroquine is an antimalarial agent also used as a disease-modifying antirheumatic drug (DMARD); it modulates immune activity by interfering with lysosomal activity and antigen presentation in immune cells, reducing autoantibody production and inflammation. The combination has been studied primarily for its potential benefits in preventing pre-eclampsia in high-risk pregnancies and for improving outcomes in systemic lupus erythematosus (SLE), including reduction of thrombosis risk[1][3][5]. Both drugs are administered orally.
- Other names
- o-Yoo-min Kim-preeclampsiaHydroxychloroquine and Aspirin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)V-ATPase (Vacuolar-type H+-ATPase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on aspirin + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + hydroxychloroquine.